* Theravance Biopharma Inc TBPH.OQ reported a quarterly
adjusted
loss of 26 cents per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -17 cents. The mean expectation of four analysts for the
quarter was for a loss of 23 cents per share. Wall Street
expected results to range from -28 cents to -19 cents per share.
* Revenue rose 7.5% to $16.87 million from a year ago;
analysts
expected $15.34 million.
* Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 26 cents.
* The company reported a quarterly loss of $12.7 million.
* Theravance Biopharma Inc shares had risen by 12.7% this
quarter and lost 19.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Theravance
Biopharma Inc is $11.00
This summary was machine generated from LSEG data November 13 at
12:08 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.23 -0.26 Missed
Jun. 30 2024 -0.21 -0.28 Missed
Mar. 31 2024 -0.25 -0.24 Beat
Dec. 31 2023 -0.15 -0.17 Missed